Cost effectivenesss of recombinant human insulin-like growth factor I therapy in patients with ALS

PharmacoEconomics

Volumn 15, Issue 2, 1999, Pages 179-195

  Ackerman, Stacey J ^a   Sullivan, Erin M ^a   Beusterien, Kathleen M ^a   Natter, Howard M ^b   Gelinas, Deborah F ^c   Patrick, Donald L ^d  

^a UK   (United States)

^b HAHNEMANN UNIVERSITY HOSPITAL   (United States)

^c Forbes Norris MDA/ALS Research Center   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RECOMBINANT SOMATOMEDIN C; RECOMBINANT PROTEIN; SOMATOMEDIN C;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; COST BENEFIT ANALYSIS; ECONOMICS; MIDDLE AGED; QUALITY OF LIFE; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; QUALITY OF LIFE; RECOMBINANT PROTEINS; SENSITIVITY AND SPECIFICITY;

EID: 0032588644     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199915020-00006     Document Type: Article

References (46)

1. 1. Incidence & Prevalence (Database Online). Mountain view: timely data resources. 1997; Nov 1996
2. 2. Klein LM, Forshew DA. The economic impact of ALS. Neurology 1996; 47 Suppl. 2: 126S-9S
3. 3. Lewis ME, Neff NT, Contreras PC, et al. Insulin-like growth factor-I for treatment of motor neuronal disorders. Exp Neurol 1993; 124: 73-88
4. 4. D'Ercole AJ, Ye P, Calikoglu AS, et al. The role of insulin-like growth factors in the central nervous system. Mol Neurobiol 1996; 13: 227-55
5. 5. The Pink Sheet. FDC Reports 1996; June 24: T&G 2-3
6. 6. Lai EC, Felice KJ, Festoff BW, et al. Effect of recombinant human insulin-like growth factor I on progression of ALS: a placebo-controlled study. Neurology 1997; 49: 1621-30
7. 7. Oddone EZ, Cowper P, Hamilton JD, et al. Cost effectiveness analysis of early zidovudine treatment of HIV infected patients. BMJ 1993; 307: 1322-5
8. 8. Garner TI, Dardis R. Cost-effectiveness analysis of end-stage renal disease treatments. Med Care 1987; 25-34
9. 9. Kattan MW, Inoue Y, Giles FJ, et al. Cost-effectiveness of interferon-alpha and conventional chemotherapy in chronic myelogenous leukemia. Ann Intern Med 1996; 125: 541-8
10. 10. Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain 1995; 118: 707-9
11. 11. Appel V, Stewart SS, Smith G, et al. A rating scale for amyotrophic lateral sclerosis: description and preliminary experience. Ann Neurol 1987; 22: 328-33
12. 12. Bergner M, Bobbitt RA, Carter WB, et al. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1981; 19: 787-805
13. 13. McGuire D, Garrison L, Armon C, et al. Relationship of the Tufts Quantitative Neuromuscular Exam (TQNE) and the Sickness Impact Profile (SIP) in measuring progression of ALS. SSNJV/CNTF ALS Study Group. Neurology 1996; 46: 1442-4
14. 14. Schulman KA, Rubenstein LE, Glick HA, et al. Relationships between sponsors and investigators in pharmacoeconomic and clinical research. Pharmacoeconomics 1995; 7: 206-20
15. 15. Hillman AL, Eisenberg JM, Pauly MV, et al. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. N Engl Med 1991; 324: 1362-5
16. 16. Lipscomb J, Weinstein MC, Torrance GW. Time preference. In: Gold MR, Weinstein MC, editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996: 214-35
17. 17. Norris FH. Care of the amyotrophic lateral sclerosis patient. In: H Mitsumoto, FH Norris, editors. Amyotrophic lateral sclerosis. A comprehensive guide to management. New York: Demos Publications, 1994: 39
18. 18. O'Brien BJ, Drummond MF, Labelle RJ, et al. In search of power and significance: Issues in the design and analysis of stochastic cost-effectiveness studies in health care. Med Care 1994; 32: 150-63
19. 19. Sacristan JA, Day SJ. Navarro O, et al. JM. Use of confidence intervals and sample size calculations in health economics studies. Ann Pharmacother 1995; 29: 719-25
20. 20. Gardiner J, Hogan A, Holmes-Rovner M, et al. Confidence intervals for cost-effectiveness ratios. Med Decis Making 1995; 15: 254-63
21. 21. Fenn P, McGuire A, Phillips V, et al. The analysis of censored treatment cost data in economic evaluation. Med Care 1995; 33: 851-63
22. 22. Ganiats TG, Miller CJ, Kaplan RM. Comparing the quality-adjusted life-year output of two treatment arms in a randomized trial. Med Care 1995; 33: 245AS-54AS
23. 23. Lee ET. Analytical estimation procedures for survival distributions. In: Statistical methods for survival data analysis. Wiley series in probability and mathematical statistics. New York: John Wiley and Sons, Inc; 1992
24. 24. Glasziou PP, Simes RJ, Gelber RD. Quality adjusted survival analysis. Stat Med 1990; 9: 1259-76
25. 25. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13: 322-38
26. 26. Drummond MF. Discussion: Torrance's 'Utility approach to measuring health-related quality of life.' J Chron Dis 1987; 40: 601-3
27. 27. Patrick DL, Starts HE, Cain KC, et al. Measuring preferences for health states worse than death. Med Decis Making 1994; 14: 9-18
28. 28. Torrance GW. Designing and conducting cost-utility analyses. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven Publishers, 1996
29. 29. Health Care Financing Administration. 1996 Medicare program: Revisions to payment policies and adjustments to the relative value units under the physician fee schedule for calendar year 1996. Federal Register 1996
30. 30. Samet JH, Libman H, Steger KA, et al. Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type I : a cross-sectional study in a municipal hospital clinic. Am J Med 1992; 92: 495-502
31. 31. Briggs A, Sculpher M, Buxton M. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ 1994; 3: 95-104
32. 32. Mooney CZ, Duval RD. Bootstrapping: a nonparametric approach to statistical inference. Newbury Park; Sage Publications Inc. 1993
33. 33. Coyle D. Statistical analysis in pharmacoeconomic studies. Pharmacoeconomics 1996; 9: 506-16
34. 34. Ringle SP, Murphy JR, Alderson MK, et al. The natural history of amyotrophic lateral sclerosis. Neurology 1993; 43: 1316-22
35. 35. Munsat TL, Andres PL, Finison L, et al. The natural history of motoneuron loss in amyotrophic lateral sclerosis. Neurology 1988; 38: 409-13
36. 36. Gubbay SS, Kahana E, Zilber N, et al. Amyotrophic lateral sclerosis. A study of its presentation and prognosis. Neurology 1985; 232: 295-300
37. 37. Norris F, Shepherd R, Denys E UK, et al. Onset, natural history and outcome in idiopathic adult motor neuron disease. J Neurol Sci 1993; 118: 48-55
38. 38. Caroscio JT, Mulvihill MN, Sterling R, et al. Amyotrophic lateral sclerosis. It's natural history. Neurol Clin 1987; 5: 1-8
39. 39. Rosen AD. Amyotrophic lateral sclerosis. Clinical features and prognosis. Arch Neurol 1978; 35: 638-42
40. 40. Welch HG, Larson EB. Cost-effectiveness of bone marrow transplantation in acute nonlymphocytic leukemia. N Engl J Med 1989; 321: 807-12
41. 41. Evans RW. Cost-effectiveness analysis of transplantation. Surg Clin North Am 1986; 66: 603-16
42. 42. US Bureau of the Census. Statistical abstract of the United States 1997. 117th ed. Washington, DC: US Bureau of the Census, 1997
43. 43. Torrance GW. Utility approach to measuring health-related quality of life. J Chron Dis 1987; 40: 593-600
44. 44. Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992; 146: 473-81
45. 45. Gold MR, Patrick DL, Torrance GW, et al. Identifying and valuing outcomes. In: Gold MR, Siegel JE, Russell LB, et al., editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996: 82-123
46. 46. McDonald ER. Psychosocial-spiritual overview. In: H Mitsumoto, FH Norris, editors. Amyotrophic lateral sclerosis: a comprehensive guide to management. New York: Demos Publications, 1994: 206-22